文献速递精神分裂症与精神病性障碍

精神分裂症复发轨迹与抗精神病药停用:五项试验个体数据Meta分析

Relapse trajectories and antipsychotic discontinuation in schizophrenia from individual participant data of five trials from the Yale Open Data Access database: a meta-analysis.
PubMed 文献 · Lancet Psychiatry · 2026-08-24

该Meta分析基于耶鲁开放数据访问项目中五项帕利哌酮停用试验的个体数据,识别出快速与延迟两种复发轨迹,快速复发者复发时症状更重且基线PANSS评分更高,但快速复发比例在停药与继续治疗组间无显著差异。

要点

  • 帕利哌酮停用后复发呈快速与延迟两种轨迹,快速复发者基线PANSS评分更高。
  • 快速复发在停药组与继续治疗组间比例无显著差异,不支持快速复发为停药药理效应。
  • 抗精神病药减停时应进行风险分层和个体化监测。

核心结论

  • 帕利哌酮停用后复发呈快速与延迟两种轨迹,快速复发与基线症状严重度相关,但快速复发并非停药组特有。

研究设计与样本

  • Meta分析纳入耶鲁开放数据访问项目中五项口服和长效针剂帕利哌酮随机双盲安慰剂对照停用试验的个体 participant 数据。
  • 纳入标准为精神分裂症或分裂情感障碍患者,先接受抗精神病药治疗超过3个月并临床稳定后随机分入安慰剂(停用)或继续活性治疗。
  • 采用潜类别混合模型分析复发前PANSS症状变化轨迹。

主要发现

  • 识别出快速和延迟两种复发轨迹,快速复发者复发时症状更严重。
  • 复发时症状谱在停药与继续治疗组间无差异。

临床怎么用

  • 抗精神病药减停过程中应进行风险分层和个体化监测,尤其关注基线症状严重度较高的患者。

局限性

  • 研究未预注册;仅纳入帕利哌酮试验,结论外推需谨慎。
  • 快速复发者基线严重度更高可能反映既存易感性或试验相关测量偏倚(筛查时症状被最小化以满足入组阈值)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Antipsychotics reduce risk of relapse in schizophrenia, but longer-term use is associated with adverse effects, often prompting dose reduction or discontinuation. Although discontinuation increases relapse risk, the clinical course is heterogeneous. Rapid relapse following antipsychotic discontinuation has been observed in clinical trials and could reflect a direct pharmacological consequence of stopping medication, as opposed to re-emergence of underlying illness. We aimed to identify distinct trajectories of symptom change preceding relapse, to examine whether trajectory membership was associated with treatment arm and baseline clinical characteristics, and to compare symptom profiles at time of relapse between individuals whose illness relapsed following discontinuation and those whose illness relapsed during continued treatment. METHODS: For this meta-analysis, on May 4, 2025, we searched the Yale University Open Data Access project database for randomised, double-blind, discontinuation trials of antipsychotics in individuals with schizophrenia or schizoaffective disorder. No language restrictions were applied. We included double-blind, placebo-controlled, relapse-prevention, randomised trials of antipsychotic medications. Studies with available individual participant data were included if participants were first treated with antipsychotic drugs for more than 3 months and clinically stabilised before they were randomly assigned to placebo (discontinuation) or continued active treatment. We excluded studies that involved diagnoses other than schizophrenia or schizoaffective disorder. We analysed longitudinal symptom data (using the Positive and Negative Syndrome Scale [PANSS]) from individuals whose illness relapsed. Latent class mixed modelling identified distinct trajectories of symptom change preceding relapse. We first examined associations between trajectory membership and treatment discontinuation or continuation. We then compared symptom profiles at both baseline and point of relapse, between both trajectory groups and discontinuation status. The study was not preregistered; the Yale University Open Data Access project ID is 2025-0740. FINDINGS: We identified five randomised, double-blind, placebo-controlled, discontinuation trials of oral and long-acting injectable (LAI) paliperidone. In our analysis, we included 271 participants from the LAI trials (155 men [57%] and 116 women [43%], mean age 38·4 years [SD 11·2, range 18-65]) and 146 from the oral trials (72 men [49%] and 74 women [51%], mean age 34·8 years [SD 11·5, range 18-61]). Two latent classes of relapse were identified: rapid and delayed onset, with rapid relapse associated with more severe symptoms at point of relapse. The proportion with rapid relapse did not differ between continuation and discontinuation groups in either LAI (discontinuation 39 [20%] of 197, continuation eight [11%] of 74; p=0·12) or oral trials (discontinuation 29 [27%] of 108, continuation ten [26%] of 38, p=0·95). Symptom profiles at relapse did not differ by discontinuation status. Across both formulations, those with rapid relapse had significantly higher baseline PANSS scores than those with delayed relapse (p<0·0010). INTERPRETATION: Relapse following paliperidone discontinuation follows two distinct trajectories, rapid and delayed, the former being related to baseline severity. We found that rapid relapse was not over-represented among those who discontinued treatment, which is not the pattern expected if rapid relapse following paliperidone discontinuation were commonly a pharmacological discontinuation effect. Higher baseline severity in rapid relapse could reflect pre-existing susceptibility, or trial-related measurement artifact whereby symptom severity is minimised at screening to meet study entry thresholds. Our findings underscore the importance of risk stratification and individualised monitoring during antipsychotic de-prescribing. FUNDING: National Institute of Health and Care Research Oxford Biomedical Research Centre and the Wellcome Trust.

来源:Lancet Psychiatry,查看原文。版权归原作者所有。

引用

  1. Louie K, Jauhar S, Rubio J, et al. Relapse trajectories and antipsychotic discontinuation in schizophrenia from individual participant data of five trials from the Yale Open Data Access database: a meta-analysis. Lancet Psychiatry. 2026. PMID: 42636852. doi:10.1016/S2215-0366(26)00225-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。